PR Newswire·Jul 30, 2026, 4:05 PM ET

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

Illumina reported Q2 2026 revenue of $1.16 billion, representing a 9.5% increase from Q2 2025.
Organic revenue growth excluding currency, acquisitions, and China impacts (ROW 1) was 8.1%.
GAAP operating margin reached 21.1%, while non-GAAP operating margin was 22.5%.
GAAP diluted earnings per share (EPS) were $1.35, and non-GAAP diluted EPS were $1.31.
The company raised its fiscal year 2026 total revenue guidance to $4.60-$4.64 billion from the previous range of $4.52-$4.62 billion.
Fiscal year 2026 ROW organic revenue growth guidance was increased to greater than 5% from the prior 2%-4% range.
Non-GAAP diluted EPS guidance for fiscal year 2026 was raised to $5.30-$5.40 from $5.15-$5.30.
Non-GAAP operating margin guidance for the full year remains unchanged at 23.4%-23.6%.
CEO Jacob Thaysen cited high demand for NovaSeq X systems & expanding multiomics capabilities as drivers for the performance.
Free cash flow for Q2 2026 was $162 million, down from $204 million in the prior year period.
Cash, cash equivalents, and short-term investments totaled $1.17 billion at the end of the quarter.
The company highlighted risks related to its inclusion on China's Unreliable Entities List & the integration of the SomaLogic acquisition.